S-1: Biotricity Eyes Capital Injection with Proposed Common Stock and Warrant Offering

Biotricity is seeking to raise capital through a best efforts offering of common stock and pre-funded warrants to support working capital and general corporate purposes.

Summary

• Biotricity is planning a best efforts offering of common stock and pre-funded warrants.
• The offering aims to raise capital for working capital and general corporate purposes.
• The company has engaged A.G.P./Alliance Global Partners as the exclusive placement agent.
• The offering includes common stock and pre-funded warrants, with the warrants offered to purchasers who would otherwise exceed beneficial ownership limits.
• The assumed public offering price is $[] per share, based on the last reported sale price on Nasdaq on February [], 2024.
• The placement agent will receive a fee equal to 7.0% of the gross proceeds, with a reduced fee of 3.5% for certain identified investors.
• The offering will terminate on [], 2024, unless closed earlier or terminated by the company.
• There is no minimum offering amount required for the closing of this offering.

Sentiment

Score: 5

Explanation: The document is neutral in tone, presenting facts about the offering without expressing strong positive or negative opinions. The risks associated with the offering are clearly outlined, balancing the potential benefits.

Positives

• The offering will provide additional capital for working capital and general corporate purposes.
• The company has engaged an experienced placement agent to assist with the offering.
• The use of pre-funded warrants allows the company to attract larger investors while managing beneficial ownership limits.

Negatives

• The offering is on a best efforts basis, so there is no guarantee that the company will raise the desired amount of capital.
• Investors will experience immediate and substantial dilution.
• The company's management has broad discretion over the use of proceeds.
• There is no public market for the pre-funded warrants.
• The company is not in compliance with certain covenants contained within certain agreements.

Risks

• The company's existing and future levels of indebtedness could adversely affect its financial health.
• The company's auditors have indicated doubt about its ability to continue as a going concern.
• The company requires additional capital to support its present business plan and its anticipated business growth.
• The company may not be able to secure additional financing.
• The failure to comply with the terms of the Credit Agreement could result in a default.
• The company's ability to make payments under the Credit Agreement depends on factors beyond its control.
• The company is not in compliance with certain covenants contained within certain agreements.
• The company's management will have broad discretion over the use of proceeds from this offering.
• This is a reasonable best efforts offering, with no minimum amount of securities required to be sold.
• Investors in this offering will not receive a refund if the company does not sell the expected amount of securities.
• If you purchase Common Stock in this offering, you will experience immediate and substantial dilution.
• The issuance of additional securities which will cause investors to experience dilution.
• This offering may cause the trading price of the company's Common Stock to decrease.
• The issuance of additional securities could adversely affect the rights of the holders of the company's Common Stock.
• The company does not intend to declare cash dividends on its shares of Common Stock in the foreseeable future.
• There is no public market for the Pre-Funded Warrants being offered in this offering.
• Holders of the Pre-Funded Warrants offered hereby will have no rights as Common Stockholders.
• The Pre-Funded Warrants are speculative in nature.
• Purchasers who purchase the company's Securities in this offering pursuant to a securities purchase agreement may have rights not available to purchasers that purchase without the benefit of a securities purchase agreement.

Future Outlook

The company intends to use the net proceeds from this offering for working capital and general corporate purposes.

Industry Context

The document does not provide specific industry context beyond the company's focus on biometric data monitoring solutions and remote patient monitoring.

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• The company will have additional capital to support its operations and growth.
• The company's employees may benefit from the increased financial stability and growth potential.

Next Steps

• The company will continue to work with the placement agent to solicit offers to purchase the securities.
• The company will negotiate the final offering price with investors.
• The company will close the offering and receive the net proceeds.

Keywords

common stock, pre-funded warrants, offering, capital raise, placement agent, Biotricity, securities